Target Profile
```
Patient's age must be greater than or equal to 18 years.
Patient must agree to use non-hormonal contraception during the study and for 6 months after the study.
Patient must not report adverse event to single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment discontinuation in the parent study.
Patient must not have historical diagnosis of Heart attack within less than or equal to 6 months.
Patient must not have active diagnosis of Unstable angina.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class II.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class III.
Patient must not have historical diagnosis of Congestive heart failure AND New York Heart Association Classification - Class IV.
Patient must not have drug allergy to ingredient trastuzumab.
Patient must not have adverse event of Grade 3 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 4 Peripheral sensory neuropathy.
Patient must not have adverse event of Grade 3 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 4 Peripheral motor neuropathy.
Patient must not have adverse event of Grade 5 Peripheral motor neuropathy.
```
